scholarly journals Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials

2003 ◽  
Vol 41 (6) ◽  
pp. 333
Author(s):  
David E. Kandzari ◽  
Vic Hasselblad ◽  
James E. Tcheng ◽  
Gregg W. Stone ◽  
Robert M. Califf ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Trials ◽  
Clinical Outcomes ◽  
Randomized Clinical Trials ◽  
Systematic Overview

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials

2004 ◽  
Vol 147 (3) ◽  
pp. 457-462 ◽  
Author(s):  
David E Kandzari ◽  
Vic Hasselblad ◽  
James E Tcheng ◽  
Gregg W Stone ◽  
Robert M Califf ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Trials ◽  
Clinical Outcomes ◽  
Randomized Clinical Trials ◽  
Systematic Overview

Treatment for acute myocardial infarction: Overview of randomized clinical trials

1996 ◽  
Vol 17 (suppl F) ◽  
pp. 16-29 ◽  
Author(s):  
S. Yusuf ◽  
S. Anand ◽  
A. Avezum ◽  
M. Flather ◽  
M. Coutinho
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Trials ◽  
Randomized Clinical Trials

Intravenous Streptokinase in Acute Myocardial Infarction

1983 ◽  
Vol 17 (5) ◽  
pp. 367-368
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Trials ◽  
Chest Pain ◽  
Intravenous Administration ◽  
Randomized Clinical Trials ◽  
Intravenous Route ◽  
Intravenous Streptokinase ◽  
Intracoronary Streptokinase ◽  
Percent Decrease

Intracoronary streptokinase has been reported to be successful in producing coronary recanalization and lowered morbidity and mortality in acute myocardial infarction patients, when administered shortly after the onset of chest pain. However, intracoronary administration of streptokinase is not practical for most hospitals at present, and intravenous administration would enable treatment of larger numbers of patients and enable the drug to be administered earlier than by the intracoronary route. Available studies have suggested benefits of the intravenous route and results of randomized clinical trials indicate an approximately 20-percent decrease in mortality after intravenous use. Intravenous streptokinase after acute myocardial infarction warrants further investigation.

Sign in / Sign up

Export Citation Format

Share Document